US 12,419,951 B2
Preparation of zinc risedronate micro/nano adjuvant and use thereof as vaccine adjuvant
Qinjian Zhao, Fujian (CN); Xiaofen Huang, Fujian (CN); Yike Li, Fujian (CN); Meifeng Nie, Fujian (CN); Siyi Chen, Fujian (CN); and Ningshao Xia, Fujian (CN)
Assigned to Xiamen University, Fujian (CN); and Xiamen Innovax Biotech Co., Ltd., Fujian (CN)
Appl. No. 17/615,493
Filed by XIAMEN UNIVERSITY, Fujian (CN); and XIAMEN INNOVAX BIOTECH CO., LTD., Fujian (CN)
PCT Filed Mar. 31, 2020, PCT No. PCT/CN2020/082443
§ 371(c)(1), (2) Date Nov. 30, 2021,
PCT Pub. No. WO2020/238394, PCT Pub. Date Dec. 3, 2020.
Claims priority of application No. 201910459715.6 (CN), filed on May 30, 2019.
Prior Publication US 2022/0233687 A1, Jul. 28, 2022
Int. Cl. A61K 39/29 (2006.01); A61K 39/25 (2006.01); A61K 39/39 (2006.01); A61P 31/22 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/39 (2013.01) [A61K 39/25 (2013.01); A61P 31/22 (2018.01); A61P 37/04 (2018.01); A61K 2039/55511 (2013.01); A61K 2039/55516 (2013.01)] 8 Claims
 
1. A vaccination method for treatment or prevention of infection in a mammal, said method comprising administering a vaccine composition intramuscularly to a mammal, wherein said vaccine composition comprises an antigen and an adjuvant, the adjuvant comprising zinc risedronate micro/nanoparticles, wherein the zinc risedronate micro/nanoparticles consist of zinc and risedronic acid and, optionally phosphate, and wherein the zinc risedronate micro/nanoparticles have a molar concentration ratio of zinc: risedronic acid of 1-8:1.